CLOROX CO /DE/
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CLX in the last 30 days.
See all $CLX insider activity →Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.
Clorox (CLX) stock rose 13.1% in a month after beating Q4 earnings and revenue estimates, with adjusted EPS of $1.66 and sales of $1.95B. The company expects fiscal 2027 sales growth of 13-14% and EPS of $5.70-$6.00, driven by GOJO acquisition and ERP benefits. However, margins remain pressured by inflation and softer demand, with gross margin declining to 41.3% in Q4. Organic sales growth is expected to be flat to slightly positive, excluding ERP effects.
Morgan Stanley, using NielsenIQ All Measured Outlets data, reported pet food and cat litter sales trends for the latest four-week period. Pet category growth rose slightly vs prior 12-week trends. Colgate-Palmolive, Freshpet, General Mills, J.M. Smucker, Mars, Nestle and Post Holdings showed differing YoY changes; Church & Dwight and Clorox led cat litter growth.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CLX (CLOROX CO /DE/). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CLX coverage spans earnings, sector analysis and financial news.
Guidance lift suggests upside for CLX if integration proceeds as expected.
Earnings beat and upbeat guidance could support further upside if margin recovery materializes.
CLX shows an acceleration in cat litter growth, which may be read as improving brand momentum.
Post-earnings guidance and acquisition context shift the near-term earnings narrative, but gross margin deterioration and EPS outlook below some expectations temper upside.
Earnings call provides forward guidance and margin/cost drivers that can reset near-term expectations for CLX’s earnings power.
alphai scores every news story that mentions CLX with an AI model for sentiment and relevance, and aggregates insider trades from CLOROX CO /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.
3 min readClorox (CLX) stock rose 13.1% in a month after beating Q4 earnings and revenue estimates, with adjusted EPS of $1.66 and sales of $1.95B. The company expects fiscal 2027 sales growth of 13-14% and EPS of $5.70-$6.00, driven by GOJO acquisition and ERP benefits. However, margins remain pressured by inflation and softer demand, with gross margin declining to 41.3% in Q4. Organic sales growth is expected to be flat to slightly positive, excluding ERP effects.
2 min readMorgan Stanley, using NielsenIQ All Measured Outlets data, reported pet food and cat litter sales trends for the latest four-week period. Pet category growth rose slightly vs prior 12-week trends. Colgate-Palmolive, Freshpet, General Mills, J.M. Smucker, Mars, Nestle and Post Holdings showed differing YoY changes; Church & Dwight and Clorox led cat litter growth.
3 min readThe article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.
6 min readClorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.
6 min readClorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.
7 min readClorox (CLX) completed its April 1 acquisition of Gojo Industries, adding Purell, which now drives more than half of net sales. For fiscal 2027, Clorox guides net sales up 13% to 14% and adjusted EPS of $5.70 to $6.00. It also raised its quarterly dividend to $1.25 and expects FCF at 11% to 13% of net sales.
6 min readClorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.
4 min readTD Cowen said Big Food categories have held up versus external factors such as GLP-1 drugs, MAHA, and SNAP cuts, but companies are losing share to premium and private-label brands. It flagged Hershey (3.7% YTD vs 4.8% category), McCormick (0.2% vs 3.2%), and others, citing margin and share risks including Conagra’s pricing and Kraft Heinz’s weak categories.
6 min readClorox (CLX) reported lower Q4 and FY2026 profit, citing year-over-year sales declines. The company posted non-GAAP EPS of $1.66 for the quarter, slightly above estimates, and revenue of $1.95B, above expectations, according to the article.
2 min read
